December 2025
The cell therapy solvent suspension tubing market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2026 to 2035. This growth is driven by emerging trends and strong demand across key sectors. The large-scale clinical and manufacturing applications of cell suspensions and tubing maintain safety and sterility in processing.
The cell therapy solvent suspension tubing market is accelerated by the rising trends and innovations in cell therapy manufacturing, which include automation, closed systems, scalable expansion, material compatibility, and single-use technologies. The industries are prioritizing heavy investments in automated and closed-loop systems to reduce contamination risks and improve efficiency. They also focus on the integration of pre-sterilized, highly reliable, and single-use tubing sets into bioreactors and processing equipment. The major players in cell therapy technologies are Terumo Blood and Cell Technologies, Borosil Scientific, Abdos Life Sciences, and Avantor/VWR, focusing on the launch of specialized products and materials for manufacturing and processing.
AI contributes to automation, process optimization, and real-time quality control across the cell therapy manufacturing sector. AI revolutionizes the cell therapy solvent suspension tubing market by assisting in reducing costs, improving efficiency, and increasing the safety of therapeutic products. AI-driven systems play a major role in process automation and monitoring, automated image analysis, anomaly and contamination detection, and process design and simulation.
Thermoplastic Elastomer (TPE)
The thermoplastic elastomer (TPE) segment dominated the market in 2025, owing to its durability, stability, and flexibility, and the wide use in the biotechnology and biopharmaceutical sectors. The TPE tubing serves as a reliable solution to transport delicate substances such as vaccines, biologics, and cell cultures. The TPE allows recycling options, which reduces waste related to single-use systems, and meets sustainability goals.
Silicone
The silicone segment is expected to grow at the fastest CAGR in the cell therapy solvent suspension tubing market during the forecast period due to its biocompatibility, non-toxicity, chemical inertness, and purity. It is flexible, durable, and maintains the purity and viability of sensitive cell suspensions. It is essential for quality control in laboratory and pharmaceutical settings.
Biopharma & Biotechnology Companies
The biopharma & biotechnology companies segment dominated the market in 2025, owing to the major role and applications of cell suspension tubing in aseptic fluid transfer and contamination control. These industries focus on process monitoring and automation support through the seamless integration of tubing systems. They prioritize cell viability, product integrity, cryopreservation, storage, scalability, and flexibility.
CMOs/CDMOs
The CMOs/CDMOs segment is estimated to grow at the fastest rate in the cell therapy solvent suspension tubing market during the predicted timeframe due to the new approaches towards closed and single-use manufacturing systems. The CDMOs and CMOs focus on improving efficiency, ensuring sterility, and meeting stringent regulatory requirements for cell and gene therapies. They also make efforts to simplify regulatory inspections by improving traceability and reducing bioburden.
| Sr. No. | Name of the Company | Headquarter | Latest Update |
| 1 | Thermo Fisher Scientific | Waltham, Massachusetts, USA | In September 2025, Thermo Fisher Scientific completed the acquisition of Solventum’s purification and filtration business. |
| 2 | Sartorius AG | Göttingen, Germany | In October 2025, Sartorius AG reported its profitable sales revenue growth of up to 7.5% in the first nine months. |
| 3 | Merck KGaA | Darmstadt, Germany | In July 2024, Merck signed an MoU with Gene Therapy Research Institution Co., Ltd. to produce viral vector-based gene therapy for Parkinson’s Disease. |
| 4 | Avantor | Radnor, Pennsylvania, USA | In October 2025, Avantor and BlueWhale Bio Partner planned to boost CAR-T manufacturing with an innovative cell activation and expansion technology. |
| 5 | RAUMEDIC | Helmbrechts, Germany | In August 2025, RAUMEDIC launched an innovative silicone tubing for increased application pressure in bio-pharma tubing. |
| 6 | Terumo Corporation | Shibuya-ku, Tokyo, Japan | In November 2025, Terumo Blood and Cell Technologies Quantum Flex Bioreactor introduced the first-ever automated 3-in-1 TCR-T manufacturing to the University of Chicago School of Medicine. |
| 7 | Lonza Group AG | Basel, Switzerland | In October 2025, Lonza expanded its product portfolio of TheraPEAK with the inclusion of AmpliCell cytokine range and TheraPEAK 293-GT medium. |
| 8 | Parker Hannifin | Cleveland, Ohio, USA | In November 2025, Parker Hannifin launched a new gap filler gel from Parker Chomerics with very high performance. |
| 9 | Danaher Corporation | Washington, D.C., U.S. | Researchers at the University of Pennsylvania and Danaher planned to improve the use of lipid nanoparticles to enable new CAR T therapies for blood cancers |
| 10 | Saint-Gobain Performance Plastics | La Défense, France | In July 2025, Qosina expanded Saint-Gobain's product offering through a new distribution partnership to manufacture high-performance tubing and polymer solutions. |
By Material Type
By End-User
By Region
December 2025
December 2025
December 2025
November 2025